Management of COVID-19 in Transplant Recipients Evolved During Pandemic renalandurologynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from renalandurologynews.com Daily Mail and Mail on Sunday newspapers.
email article
Non-calcium-based phosphate binders weren t any better at reducing cardiovascular events than calcium-based binders in dialysis patients, the LANDMARK trial determined.
In the open-label randomized trial of over 2,300 Japanese patients on hemodialysis, there were no significant differences in composite cardiovascular events between the lanthanum carbonate group versus the calcium carbonate group (HR 1.11, 95% CI 0.88-1.41,
P=0.37), reported Hiroaki Ogata, MD, of Showa University Northern Yokohama Hospital in Kanagawa, Japan, and colleagues.
These heart events included cardiovascular death, nonfatal myocardial infarction or stroke, unstable angina, transient ischemic attack, or hospitalization for heart failure or ventricular arrhythmia, the group explained in
During the median 3.16-year follow-up period, 147 of 1,063 dialysis patients using lanthanum carbonate experienced cardiovascular events compared with 134 of 1,072 patients in the calcium carbonate gro
(RGLS) - Regulus Therapeutics' RGLS4326 Reports Mixed Bag On Polycystic Kidney Disease-Associated Biomarker Study benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
email article
The investigational hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor vadadustat was noninferior to the erythropoiesis-stimulating agent darbepoetin alfa for treating anemia in chronic kidney disease (CKD) patients, a pair of phase III trials found.
2TECT Study of non-dialysis-dependent CKD treatment with vadadustat met the pre-specified noninferiority endpoint for hematologic efficacy compared with darbepoetin alfa, reported Glenn Chertow, MD, MPH, of Stanford University School of Medicine in California, and colleagues.
Looking only at ESA-untreated patients, there was an average between-group hemoglobin concentration difference of 0.05 g/dL (95% CI -0.04 to 0.15) maintained from weeks 24 to 36 with vadadustat or darbepoetin alfa treatment.